MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Disease-modifying strategies"

  • 2017 International Congress

    Development of a prototype alpha-synuclein vaccine to induce T regulatory cells for the treatment of synucleonopathy

    E. Rockenstein, G. Ostroff, F. Dikengil, F. Rus, M. Mante, J. Florio, A. Adame, I. Trinh, E. Masliah, R. Rissman (La Jolla, CA, USA)

    Objective: Test the hypothesis that combining humoral and immunosuppressive cellular asyn immunization will enhance asyn clearance, and reduce inflammation and neuropathological symptoms in a human…
  • 2017 International Congress

    Results From a Phase 1b Multiple Ascending-Dose Study of PRX002, an Anti–Alpha-Synuclein Monoclonal Antibody, in Patients with Parkinson’s Disease

    J. Jankovic, I. Goodman, B. Safirstein, D. Schenk, G. Kinney, M. Koller, D. Ness, S. Griffith, M. Grundman, J. Soto, S. Ostrowitzki, F. Boess, M. Martin-Facklam, J. Quinn, S. Isaacson, D. Jennings, O. Omidvar, A. Ellenbogen (Houston, TX, USA)

    Objective: To evaluate PRX002 in patients with PD in a double-blind, placebo-controlled, phase 1b multiple ascending-dose study. Background: PRX002 (RG7935) is an investigational monoclonal antibody…
  • 2017 International Congress

    Targeting alpha-Synuclein Aggregation for the Treatment of Parkinson’s Disease

    E. Tsika, E. Gabellieri, A. Davranche, C. Boudou, M. Ravache, L. Grasso, S. Nampally, H. Haddouk, J. Wettstein, A. Pfeifer, A. Muhs (Lausanne, Switzerland)

    Objective: To develop small molecular weight compounds (SMEs) as disease-modifying agents, which are designed to arrest or even reverse the aggregation process of alpha-synuclein (aSyn)…
  • 2017 International Congress

    Randomized Parkinson’s Trial of GDNF Administered via Intermittent Intraputamenal Convection-Enhanced Delivery.

    T.G. Study Group (Bristol, United Kingdom)

    Objective: Assesing the neurorestorative effect of GDNF.  Background: GDNF is a potent neurotrophic factor. A previous placebo-controlled trial, however, at 6 months, failed to demonstrate…
  • 2017 International Congress

    Communication Calendar for Interdisciplinary Therapy of Parkinson’s Disease

    F. Adib Saberi, D. Dressler (Hamburg, Germany)

    Objective: To develop a communication calendar (CC) to facilitate information exchange about outpatients treated by various therapists in order to optimize interdisciplinary therapy of Parkinson's…
  • 2017 International Congress

    Physical activity habits in early Parkinson’s disease and healthy controls

    A. Amara, N. Seedorff, L. Chahine, K. Kieburtz, C. Caspell-Garcia, T. Simuni (Birmingham, AL, USA)

    Objective: Investigate the physical activity habits of Parkinson’s disease (PD) and healthy control (HC) participants of the PPMI cohort.  Background: Exercise can improve the motor…
  • 2017 International Congress

    Identification of a trehalose treatment regimen with potential to be translated into a therapeutic for the treatment of Parkinson’s disease

    J. Koprich, P. Howson, T. Johnston, M. Hill, P. Ravenscroft, J. Brotchie (Toronto, ON, Canada)

    Objective: To evaluate the preclinical efficacy of trehalose and to identify a dosing regimen that can be used to clinically evaluate trehalose as a disease-modifying therapy…
  • 2017 International Congress

    Clinical and Imaging and phenoconversion in the PARS prodromal cohort

    K. Marek, A. Siderowf, S. Eberly, D. Oakes, M. Stern, D. Russell, J. Seibyl, D. Jennings (New Haven, CT, USA)

    Objective: We report clinical and imaging phenoconversion data at 6 years follow-up for the PARS cohort. Background: The PARS cohort consists of 203 hyposmic and…
  • 2017 International Congress

    Neuroprotective effects of antidepressant mirtazapine against dopaminergic neurodegeneration in cultured cells and in parkinsonian mice possibly by targeting astrocytes

    M. Asanuma, I. Miyazaki, R. Kikuoka, S. Murakami, N. Isooka, Y. Kitamura (Okayama, Japan)

    Objective: In this study, we examined neuroprotective effects of mirtazapine and involvement of astrocytes in the effects using primary cultured cells and parkinsonian mice. Background:…
  • 2017 International Congress

    Higher genetic load is associated with an earlier disease onset but not with more rapid disease progression in Parkinson’s disease

    S. Lerche, I. Wurster, B. Roeben, E. Schaeffer, C. Schulte, S. Akbas, A.-K. Hauser, C. Deuschle, T. Gasser, D. Berg, K. Brockmann (Tuebingen, Germany)

    Objective: To evaluate the influence of genetic variants on phenotypic variability and disease progression in PD patients. Background: Parkinson’s disease (PD) patients show a large…
  • « Previous Page
  • 1
  • …
  • 18
  • 19
  • 20
  • 21
  • 22
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley